GPHN (Gephyrin): Synaptic Scaffold and Molybdenum Cofactor Biosynthesis Gene

A dual-function gene encoding gephyrin, essential for inhibitory synaptic clustering and molybdenum cofactor synthesis; implicated in neurological disorders and cancer.

Gene Information Card

Symbol GPHN
Full Name Gephyrin
Gene Type Protein coding
Chromosomal Location 14q23.3
NCBI Gene ID 10243 ncbi.nlm.nih.gov/gene/10243
Ensembl ID ENSG00000171723
UniProt ID Q9NQX3
OMIM ID 603930
HGNC ID 15465
Aliases GPH, gephyrin, MOCS1D, GPHRN

Description

GPHN encodes gephyrin, a multifunctional protein that acts as a scaffold for inhibitory neurotransmitter receptors (GABA-A and glycine receptors) at postsynaptic sites, and also participates in molybdenum cofactor biosynthesis. Mutations in GPHN are associated with hyperekplexia, epilepsy, and autism spectrum disorders, and altered expression is observed in various cancers.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Hyperekplexia Loss-of-function mutations impair gephyrin's synaptic clustering function, leading to disrupted glycinergic neurotransmission and exaggerated startle response. ClinVar, OMIM
Epilepsy Mutations affecting gephyrin function may reduce inhibitory synaptic strength, contributing to neuronal hyperexcitability and seizures. ClinVar, PubMed
Autism spectrum disorder Rare variants in GPHN have been identified in ASD cohorts, suggesting a role in synaptic dysfunction underlying neurodevelopmental phenotypes. ClinVar, PubMed
Molybdenum cofactor deficiency GPHN mutations can impair molybdenum cofactor synthesis, leading to severe neurological symptoms due to sulfite oxidase deficiency. OMIM, PubMed
Cancer Altered GPHN expression is observed in several tumor types, potentially affecting cell adhesion and migration, though mechanistic details are emerging. COSMIC, PubMed

Expression Profile

Tissue Expression
Tissue nTPM level
Brain High High
Adrenal gland Medium Medium
Kidney Medium Medium
Liver Low Low
Heart Low Low
Cell Line Expression
Cell Line nTPM Notes
SH-SY5Y (neuroblastoma) High Neuronal-like expression
U87MG (glioblastoma) Medium Glial expression
HepG2 (hepatocellular carcinoma) Low Low expression
A549 (lung carcinoma) Low Low expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.1129C>T (p.Arg377Ter) Nonsense Rare Loss of function, associated with hyperekplexia
c.491A>G (p.Tyr164Cys) Missense Rare Impaired synaptic clustering, epilepsy
c.1045G>A (p.Gly349Ser) Missense Rare Reduced molybdenum cofactor synthesis
c.1390C>T (p.Arg464Trp) Missense Rare Dominant negative effect on gephyrin oligomerization
Mutation functional classification

Loss of Function (LOF)

Nonsense and frameshift mutations leading to truncated gephyrin protein, resulting in loss of synaptic clustering and molybdenum cofactor synthesis.

Gain of Function (GOF)

Not well documented; no clear gain-of-function mutations reported.

Dominant Negative (DN)

Missense mutations in the oligomerization domain can disrupt multimer formation, exerting a dominant-negative effect on wild-type gephyrin.

Pathways

• Molybdenum cofactor biosynthesis
• GABAergic synapse
• Glycinergic synapse
• Postsynaptic density organization

Protein Summary

Gephyrin is a 736-amino acid protein that forms hexameric scaffolds at inhibitory synapses, anchoring glycine and GABA-A receptors via interactions with cytoskeletal elements. It also contains domains for molybdenum cofactor synthesis, with an N-terminal G-domain and C-terminal E-domain that catalyze molybdopterin adenylation and insertion. Alternative splicing generates isoforms with tissue-specific functions.

Related Products

Product name Cat.No. Species Gene ID
GPHN Knockout HEK293 Cell Line EDJ-KQ6345 Human 10243 Details Get a Quote
GPHN Knockout A-549 Cell Line EDJ-KQ31672 Human 10243 Details Get a Quote
GPHN Knockout HCT 116 Cell Line EDJ-KQ31673 Human 10243 Details Get a Quote
GPHN Knockout HeLa Cell Line EDJ-KQ31674 Human 10243 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: